Syngene Collaborates with Johns Hopkins University to Advance Early-Stage Drug Discovery

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced a strategic collaboration with Johns Hopkins University, MD, U.S., to advance early‑stage drug discovery programs and platform technologies emerging from the university’s research labs.

The collaboration will be delivered by Syngene SynVent™, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development. Syngene’s Connector model, which is designed to bridge high-potential, early-stage assets and technology platforms with strategic investors and downstream partnerships will be leveraged to bring together relevant stakeholders to sponsor research and secure licensing options for the resulting intellectual property.

Kenneth Barr, Senior Vice President, Head of Strategic Collaborations, Syngene International, said, “We are delighted to be working with a renowned institution like Johns Hopkins. We are uniquely positioned to translate pioneering research into credible therapeutic candidates, and our goal is to significantly compress the time required for high‑potential programs to become clinically relevant, creating a faster and more efficient pipeline of new medicines.”

According to Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, this novel collaboration model has the potential to link discoveries from Johns Hopkins laboratories with the drug discovery capabilities of Syngene, pharmaceutical and biotech partners, and investors – accelerating groundbreaking innovations developed at Johns Hopkins and turning promising science into credible development programs that could ultimately lead to new options for patients.